Laura Aguilar MD, PhD

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

Articles by Laura Aguilar MD, PhD

The Potential to Apply Immunotherapy DOC1021 to a Broad Array of Tumor Types

June 2nd 2025

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Evaluating Immunotherapy DOC1021 for Glioblastoma

ByLaura Aguilar MD, PhD,Noah Stansfield

June 2nd 2025

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.

Laura Aguilar, MD, PhD, on the Potential to Apply Immunotherapy DOC1021 to a Broad Array of Tumor Types

ByLaura Aguilar MD, PhD,Noah Stansfield

June 1st 2025

The chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.